- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT02650401
Studio di Entrectinib (Rxdx-101) in bambini e adolescenti con tumori del SNC localmente avanzati o metastatici solidi o primari e/o che non hanno opzioni terapeutiche soddisfacenti (STARTRK-NG)
Uno studio di fase 1/2, in aperto, di aumento della dose e di espansione di Entrectinib (Rxdx-101) in pediatria con tumori del SNC solidi o primari localmente avanzati o metastatici e/o che non hanno opzioni terapeutiche soddisfacenti
This is an open-label, Phase 1/2 multicenter dose escalation study in pediatric patients with relapsed or refractory extracranial solid tumors (Phase 1), with additional expansion cohorts (Phase 2) in patients with primary brain tumors harboring NTRK1/2/3 or ROS1 gene fusions, and extracranial solid tumors harboring NTRK1/2/3 or ROS1 gene fusions.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 2
- Fase 1
Contatti e Sedi
Luoghi di studio
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 1X8
- The Hospital for Sick Children
-
-
-
-
-
Beijing, Cina
- Beijing Children's Hospital, Capital Medical University
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Cina, 200082
- Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
-
-
-
-
-
Lyon, Francia, 69373
- Centre Leon Berard
-
Marseille, Francia, 13385
- Hôpital de la Timone, Oncologie Pédiatrique
-
-
-
-
Baden-Wurttemberg
-
Heidelberg, Baden-Wurttemberg, Germania, 69120
- Universitaetsklinikum Heidelberg
-
-
-
-
-
Hong Kong, Hong Kong, 00000
- Hong Kong Children's Hospital
-
-
-
-
Lombardy
-
Milan, Lombardy, Italia, 20133
- Fondazione IRCCS Istituto Nazionale dei Tumori
-
-
-
-
-
London, Regno Unito, SW3 6JJ
- Royal Marsden Hospital (Sutton)
-
Newcastle upon Tyne, Regno Unito, NE1 4LP
- Royal Victoria Infirmary
-
-
-
-
-
Madrid, Spagna, 28009
- Hospital Infantil Universitario Nino Jesus
-
-
-
-
California
-
La Jolla, California, Stati Uniti, 92093-0706
- University of California San Diego
-
San Francisco, California, Stati Uniti, 94158
- UCSF Benioff Children's Hospital
-
-
Colorado
-
Aurora, Colorado, Stati Uniti, 80045
- Children's Hospital Colorado
-
-
Georgia
-
Atlanta, Georgia, Stati Uniti, 30322
- Egleston Children's Hospital at Emory University Atlanta
-
-
Illinois
-
Chicago, Illinois, Stati Uniti, 60637
- University of Chicago
-
-
Maryland
-
Baltimore, Maryland, Stati Uniti, 21205
- Johns Hopkins University
-
-
Massachusetts
-
Boston, Massachusetts, Stati Uniti, 02215
- Dana Farber Cancer Institute
-
-
Missouri
-
St Louis, Missouri, Stati Uniti, 63110
- Washington University,St. Louis Children's Hospital
-
-
New York
-
New York, New York, Stati Uniti, 10065
- Memorial Sloan Kettering Cancer Center
-
-
Ohio
-
Columbus, Ohio, Stati Uniti, 43205
- Nationwide Children's Hospital
-
-
Oregon
-
Portland, Oregon, Stati Uniti, 97239
- Oregon Health & Science Uni
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Stati Uniti, 19104
- Children's Hospital of Philadelphia
-
-
Tennessee
-
Memphis, Tennessee, Stati Uniti, 38105
- St. Jude Children'S Research Hospital
-
-
Texas
-
Houston, Texas, Stati Uniti, 77030
- Texas Children's Cancer and Hematology Center
-
-
Utah
-
Salt Lake City, Utah, Stati Uniti, 84113
- Primary Children's Hospital
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
-
Disease status:
-
Phase 1 portion (closed): Participants must have measurable or evaluable disease, as defined by RECIST v1.1
-
Phase 2 portion:
- Part B: Participants must have measurable or evaluable disease, as defined by RANO
- Part C (closed): Participants must have measurable or evaluable disease, as defined by RECIST v1.1 ± Curie Scale
- Part D: Participants must have measurable or evaluable disease, as defined by RECIST v1.1
- Part E (closed): Participants must have measurable or evaluable disease, as defined by RECIST v1.1 ± Curie Scale or RANO
-
-
Tumor type:
-
Phase 1 portion:
* Part A: Relapsed or refractory extracranial solid tumors
-
Phase 2 portion
- Part B: Primary brain tumors with NTRK1/2/3 or ROS1 gene fusions; gene fusions are defined as those predicted to translate into a fusion protein with a functional TRKA/B/C or ROS1 kinase domain, without a concomitant second oncodriver as determined by a nucleic acid-based diagnostic testing method
- Part D: Extracranial solid tumors (including NB) with NTRK1/2/3 or ROS1 gene fusions; gene fusions are defined as those predicted to translate into a fusion protein with a functional TRKA/B/C or ROS1 kinase domain, without a concomitant second oncodriver as determined by a nucleic acid-based diagnostic testing method
-
-
Histologic/molecular diagnosis of malignancy at diagnosis or the time of relapse
-
Archival tumor tissue from diagnosis or, preferably, at relapse
-
Performance status: Lansky or Karnofsky score ≥ 60% and minimum life expectancy of at least 4 weeks
-
Prior therapy: Participants must have a disease that is locally advanced, metastatic, or where surgical resection is likely to result in severe morbidity, and who have no satisfactory treatment options for solid tumors and primary CNS tumors that are neurotrophic tyrosine receptor kinase (NTRK) or ROS1 fusion-positive
-
Participants must have recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to enrollment
-
Adequate organ and neurologic function
-
Females of childbearing potential must have a negative serum pregnancy test during screening and be neither breastfeeding nor intending to become pregnant during study participation. Agreement to remain abstinent or use use combined contraceptive methods prior to study entry, for the duration of study participation and in the following 90 days after discontinuation of study treatment.
-
For male participants with a female partner of childbearing potential or a pregnant female partner: Agreement to remain abstinent or use a condom during the treatment period and for at least 3 months after the last dose of study drug
Exclusion Criteria:
- Receiving other experimental therapy
- Known congenital long QT syndrome
- History of recent (3 months) symptomatic congestive heart failure or ejection fraction ≤50% at screening
- Known active infections
- Familial or personal history of congenital bone disorders, bone metabolism alterations or osteopenia
- Receiving Enzyme Inducing Antiepileptic Drugs (EIAEDs) within 14 days of first dose.
- Prior treatment with approved or investigational TRK or ROS1 inhibitors
- Known hypersensitivity to entrectinib or any of the other excipients of the investigational medicinal product
- Patients with NB with bone marrow space-only disease
- Incomplete recovery from acute effects of any surgery prior to treatment.
- Active gastrointestinal disease or other malabsorption syndromes that would impact drug absorption.
- Other severe acute or chronic medical or psychiatric condition or lab abnormality that may increase the risk associated with study participation, drug administration or may interfere with the interpretation of study results.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Non randomizzato
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Comparatore attivo: Extracranial solid tumors harboring NTRK1/2/3,
Arm closed for further enrollment ROS1, ALK non-gene fusion molecular alterations Oral entrectinib (RXDX-101) |
TRKA/B/C, ROS1, and ALK inhibitor
Altri nomi:
|
|
Comparatore attivo: CNS tumors harboring- NTRK1/2/3, ROS1, ALK
Arm closed for further enrollment molecular alterations, including gene fusions Oral entrectinib (RXDX-101) |
TRKA/B/C, ROS1, and ALK inhibitor
Altri nomi:
|
|
Comparatore attivo: Neuroblastoma
Arm closed for further enrollment Oral entrectinib (RXDX-101) |
TRKA/B/C, ROS1, and ALK inhibitor
Altri nomi:
|
|
Comparatore attivo: Non-neuroblastoma, extracranial solid tumors
Arm closed for further enrollment harboring - NTRK1/2/3, ROS1, ALK gene fusions Oral entrectinib (RXDX-101) |
TRKA/B/C, ROS1, and ALK inhibitor
Altri nomi:
|
|
Comparatore attivo: Any participant unable to swallow capsules
Arm closed for further enrollment Any participant who otherwise meet all other eligibility criteria Oral entrectinib (RXDX-101) |
TRKA/B/C, ROS1, and ALK inhibitor
Altri nomi:
|
|
Comparatore attivo: Expansion: CNS tumors harboring NTRK1/2/3, ROS1
gene fusions Oral entrectinib (RXDX-101) |
TRKA/B/C, ROS1, and ALK inhibitor
Altri nomi:
|
|
Comparatore attivo: Expansion: Extracranial solid tumors harboring NTRK1/2/3, ROS1
NTRK 1,2,3 and ROS1 fusions Oral entrectinib (RXDX-101) |
TRKA/B/C, ROS1, and ALK inhibitor
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Maximum Tolerated Dose (MTD)
Lasso di tempo: Approximately 6 months
|
Assessed by National Cancer Institute Common Terminology for Adverse Events Criteria (NCI CTCAE v4.03) |
Approximately 6 months
|
|
Recommended Phase 2 Dose (RP2D) of F1 Formulation In Pediatric Participants Able To Swallow Intact Capsules
Lasso di tempo: Approximately 6 months
|
Assessed by NCI CTCAE v4.03 |
Approximately 6 months
|
|
Recommended Phase 2 Dose (RP2D) of F06 Formulation In Pediatric Participants Able To Swallow Intact Capsules
Lasso di tempo: Approximately 6 months
|
Assessed by NCI CTCAE v4.03 |
Approximately 6 months
|
|
Recommended Phase 2 Dose (RP2D) of F06 Formulation In Pediatric In Participants Dosed Via Feeding Tube (Nasogastric Tube Or Gastric Tube)
Lasso di tempo: Approximately 6 months
|
Assessed by NCI CTCAE v4.03 |
Approximately 6 months
|
|
Recommended Phase 2 Dose (RP2D) Of Minitablets/F15 Formulation In Pediatric Participants Unable To Swallow Intact Capsules
Lasso di tempo: Approximately 6 months
|
Assessed by NCI CTCAE v4.03 |
Approximately 6 months
|
|
Cohort B: Objective Response Rate (ORR)
Lasso di tempo: Approximately 6 months
|
Assessed by RANO per the BICR |
Approximately 6 months
|
|
Cohort D: ORR
Lasso di tempo: Approximately 6 months
|
Assessed by RECIST v1.1 per the BICR |
Approximately 6 months
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Safety and Tolerability - AE, ECG and Labs assessed by NCI CTCAE v4.03
Lasso di tempo: Approximately 24 months
|
AE, ECG and Labs assessed by NCI CTCAE v4.03 |
Approximately 24 months
|
|
Maximum observed plasma drug concentration (Cmax) using F1 Formulation
Lasso di tempo: Approximately 24 months
|
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Approximately 24 months
|
|
Maximum observed plasma drug concentration (Cmax) using F06 Formulation given intact
Lasso di tempo: Approximately 24 months
|
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Approximately 24 months
|
|
Maximum observed plasma drug concentration (Cmax) using F06 Formulation administered via feeding tube
Lasso di tempo: Approximately 24 months
|
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Approximately 24 months
|
|
Maximum observed plasma drug concentration (Cmax) using minitablets/F15
Lasso di tempo: Approximately 24 months
|
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Approximately 24 months
|
|
Time to Cmax, by inspection (Tmax) using F1 Formulation
Lasso di tempo: Approximately 24 months
|
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Approximately 24 months
|
|
Time to Cmax, by inspection (Tmax) using F06 Formulation given intact
Lasso di tempo: Approximately 24 months
|
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Approximately 24 months
|
|
Time to Cmax, by inspection (Tmax) using F06 Formulation administered via feeding tube
Lasso di tempo: Approximately 24 months
|
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Approximately 24 months
|
|
Time to Cmax, by inspection (Tmax) using minitablets/F15
Lasso di tempo: Approximately 24 months
|
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Approximately 24 months
|
|
AUC at steady state (AUCss) using F1 Formulation
Lasso di tempo: Approximately 24 months
|
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Approximately 24 months
|
|
AUC at steady state (AUCss) using F06 Formulation given intact
Lasso di tempo: Approximately 24 months
|
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Approximately 24 months
|
|
AUC at steady state (AUCss) using F06 Formulation administered via feeding tube
Lasso di tempo: Approximately 24 months
|
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Approximately 24 months
|
|
AUC at steady state (AUCss) using minitablets/F15
Lasso di tempo: Approximately 24 months
|
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Approximately 24 months
|
|
Terminal half life (t½) using F1 Formulation
Lasso di tempo: Approximately 24 months
|
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Approximately 24 months
|
|
Terminal half life (t½) using F06 Formulation given intact
Lasso di tempo: Approximately 24 months
|
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Approximately 24 months
|
|
Terminal half life (t½) using F06 Formulation administered via feeding tube
Lasso di tempo: Approximately 24 months
|
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Approximately 24 months
|
|
Terminal half life (t½) using minitablets/F15
Lasso di tempo: Approximately 24 months
|
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Approximately 24 months
|
|
Area under the drug concentration by time curve (AUC) using F1 Formulation
Lasso di tempo: Approximately 24 months
|
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Approximately 24 months
|
|
Area under the drug concentration by time curve (AUC) using F06 Formulation given intact
Lasso di tempo: Approximately 24 months
|
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Approximately 24 months
|
|
Area under the drug concentration by time curve (AUC) using F06 Formulation administered via feeding tube
Lasso di tempo: Approximately 24 months
|
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Approximately 24 months
|
|
Area under the drug concentration by time curve (AUC) using minitablets/F15
Lasso di tempo: Approximately 24 months
|
Assessed by plasma concentrations obtained on Days 1, 2, 8, 15, 22 (Cycle 1), Days 1, 2 (Cycle 2) and on Day 1 of every cycle thereafter |
Approximately 24 months
|
|
Cohort A, D, or E: Clinical Benefit Rate (CBR)
Lasso di tempo: Approximately 6 months
|
Assessed by RECIST v1.1 per the BICR and investigator |
Approximately 6 months
|
|
Cohort B or E: CBR
Lasso di tempo: Approximately 6 months
|
Assessed by RANO per the BICR and investigator |
Approximately 6 months
|
|
Cohort C: CBR
Lasso di tempo: Approximately 6 months
|
Assessed by the Curie scale per the BICR and investigator |
Approximately 6 months
|
|
Cohort A, D, or E: Progression-free Survival (PFS)
Lasso di tempo: Approximately 6 months
|
Assessed by RECIST v1.1 per the BICR and investigator |
Approximately 6 months
|
|
Cohort B or E: PFS
Lasso di tempo: Approximately 6 months
|
Assessed by RANO per the BICR and investigator |
Approximately 6 months
|
|
Cohort C: PFS
Lasso di tempo: Approximately 6 months
|
Assessed by the Curie scale per the BICR and investigator |
Approximately 6 months
|
|
Cohort A, D, or E: Overall Survival (OS)
Lasso di tempo: Approximately 6 months
|
Assessed by RECIST v1.1 |
Approximately 6 months
|
|
Cohort B or E: OS
Lasso di tempo: Approximately 6 months
|
Assessed by RANO |
Approximately 6 months
|
|
Cohort A, D, or E: ORR
Lasso di tempo: Approximately 6 months
|
Assessed by RECIST v1.1 per the BICR and investigator |
Approximately 6 months
|
|
Cohort B or E: ORR
Lasso di tempo: Approximately 6 months
|
Assessed by RANO per the BICR and investigator |
Approximately 6 months
|
|
Cohort C: ORR
Lasso di tempo: Approximately 6 months
|
Assessed by the Curie scale per the BICR and investigator |
Approximately 6 months
|
|
Cohort A, D, or E: Time to response (TTR)
Lasso di tempo: Approximately 6 months
|
Assessed by RECIST v1.1 per the BICR and investigator |
Approximately 6 months
|
|
Cohort B or E: TTR
Lasso di tempo: Approximately 6 months
|
Assessed by RANO per the BICR and investigator |
Approximately 6 months
|
|
Cohort C: TTR
Lasso di tempo: Approximately 6 months
|
Assessed by the Curie scale per the BICR and investigator |
Approximately 6 months
|
|
Cohort A, D, or E: Duration of Response (DOR)
Lasso di tempo: Approximately 6 months
|
Assessed by RECIST v1.1 per the BICR and investigator |
Approximately 6 months
|
|
Cohort B or E: DOR
Lasso di tempo: Approximately 6 months
|
Assessed by RANO per the BICR and investigator |
Approximately 6 months
|
|
Cohort C: DOR
Lasso di tempo: Approximately 6 months
|
Assessed by the Curie scale per the BICR and investigator |
Approximately 6 months
|
|
Phase 2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort B or E): ORR
Lasso di tempo: Approximately 6 months
|
Assessed by RANO per the investigator |
Approximately 6 months
|
|
Phase 2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort D or E): ORR
Lasso di tempo: Approximately 6 months
|
Assessed by RECIST v1.1 per the investigator |
Approximately 6 months
|
|
Phase 1/2 Participants with NTRK1/2/3 gene fusions (Cohort A, D, or E): ORR
Lasso di tempo: Approximately 6 months
|
Assessed by RECIST v1.1 per the BICR and investigator |
Approximately 6 months
|
|
Phase 1/2 Participants with NTRK1/2/3 gene fusions (Cohort B or E): ORR
Lasso di tempo: Approximately 6 months
|
Assessed by RANO per the BICR and investigator |
Approximately 6 months
|
|
Phase 1/2 Participants with ROS1 gene fusions (Cohort A, D, or E): ORR
Lasso di tempo: Approximately 6 months
|
Assessed by RECIST v1.1 per the BICR and investigator |
Approximately 6 months
|
|
Phase 1/2 Participants with ROS1 gene fusions (Cohort B or E): ORR
Lasso di tempo: Approximately 6 months
|
Assessed by RANO per the BICR and investigator |
Approximately 6 months
|
|
Phase 1/2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort A, D, or E): ORR
Lasso di tempo: Approximately 6 months
|
Assessed by RECIST v1.1 per the BICR and investigator |
Approximately 6 months
|
|
Phase 1/2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort B or E): ORR
Lasso di tempo: Approximately 6 months
|
Assessed by RANO per the BICR and investigator |
Approximately 6 months
|
|
Phase 2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort B or E): DOR
Lasso di tempo: Approximately 6 months
|
Assessed by RANO per the BICR and investigator |
Approximately 6 months
|
|
Phase 2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort D or E): DOR
Lasso di tempo: Approximately 6 months
|
Assessed by RECIST v1.1 per the BICR and investigator |
Approximately 6 months
|
|
Phase 1/2 Participants with NTRK1/2/3 gene fusions (Cohort A, D, or E): DOR
Lasso di tempo: Approximately 6 months
|
Assessed by RECIST v1.1 per the BICR and investigator |
Approximately 6 months
|
|
Phase 1/2 Participants with NTRK1/2/3 gene fusions (Cohort B or E): DOR
Lasso di tempo: Approximately 6 months
|
Assessed by RANO per the BICR and investigator |
Approximately 6 months
|
|
Phase 1/2 Participants with ROS1 gene fusions (Cohort A, D, or E): DOR
Lasso di tempo: Approximately 6 months
|
Assessed by RECIST v1.1 per the BICR and investigator |
Approximately 6 months
|
|
Phase 1/2 Participants with ROS1 gene fusions (Cohort B or E): DOR
Lasso di tempo: Approximately 6 months
|
Assessed by RANO per the BICR and investigator |
Approximately 6 months
|
|
Phase 1/2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort A, D, or E): DOR
Lasso di tempo: Approximately 6 months
|
Assessed by RECIST v1.1 per the BICR and investigator |
Approximately 6 months
|
|
Phase 1/2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort B or E): DOR
Lasso di tempo: Approximately 6 months
|
Assessed by RANO per the BICR and investigator |
Approximately 6 months
|
|
Phase 2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort B or E): TTR
Lasso di tempo: Approximately 6 months
|
Assessed by RANO per the BICR and investigator |
Approximately 6 months
|
|
Phase 2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort D or E): TTR
Lasso di tempo: Approximately 6 months
|
Assessed by RECIST v1.1 per the BICR and investigator |
Approximately 6 months
|
|
Phase 1/2 Participants with NTRK1/2/3 gene fusions (Cohort A, D, or E): TTR
Lasso di tempo: Approximately 6 months
|
Assessed by RECIST v1.1 per the BICR and investigator |
Approximately 6 months
|
|
Phase 1/2 Participants with NTRK1/2/3 gene fusions (Cohort B or E): TTR
Lasso di tempo: Approximately 6 months
|
Assessed by RANO per the BICR and investigator |
Approximately 6 months
|
|
Phase 1/2 Participants with ROS1 gene fusions (Cohort A, D, or E): TTR
Lasso di tempo: Approximately 6 months
|
Assessed by RECIST v1.1 per the BICR and investigator |
Approximately 6 months
|
|
Phase 1/2 Participants with ROS1 gene fusions (Cohort B or E): TTR
Lasso di tempo: Approximately 6 months
|
Assessed by RANO per the BICR and investigator |
Approximately 6 months
|
|
Phase 1/2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort A, D, or E): TTR
Lasso di tempo: Approximately 6 months
|
Assessed by RECIST v1.1 per the BICR and investigator |
Approximately 6 months
|
|
Phase 1/2 Participants with NTRK1/2/3 or ROS1 gene fusions (Cohort B or E): TTR
Lasso di tempo: Approximately 6 months
|
Assessed by RANO per the BICR and investigator |
Approximately 6 months
|
Collaboratori e investigatori
Sponsor
Investigatori
- Direttore dello studio: Clinical Trials, Hoffmann-La Roche
Pubblicazioni e link utili
Pubblicazioni generali
- Desai AV, Robinson GW, Gauvain K, Basu EM, Macy ME, Maese L, Whipple NS, Sabnis AJ, Foster JH, Shusterman S, Yoon J, Weiss BD, Abdelbaki MS, Armstrong AE, Cash T, Pratilas CA, Corradini N, Marshall LV, Farid-Kapadia M, Chohan S, Devlin C, Meneses-Lorente G, Cardenas A, Hutchinson KE, Bergthold G, Caron H, Chow Maneval E, Gajjar A, Fox E. Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG). Neuro Oncol. 2022 Oct 3;24(10):1776-1789. doi: 10.1093/neuonc/noac087.
- Doebele RC, Drilon A, Paz-Ares L, Siena S, Shaw AT, Farago AF, Blakely CM, Seto T, Cho BC, Tosi D, Besse B, Chawla SP, Bazhenova L, Krauss JC, Chae YK, Barve M, Garrido-Laguna I, Liu SV, Conkling P, John T, Fakih M, Sigal D, Loong HH, Buchschacher GL Jr, Garrido P, Nieva J, Steuer C, Overbeck TR, Bowles DW, Fox E, Riehl T, Chow-Maneval E, Simmons B, Cui N, Johnson A, Eng S, Wilson TR, Demetri GD; trial investigators. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol. 2020 Feb;21(2):271-282. doi: 10.1016/S1470-2045(19)30691-6. Epub 2019 Dec 11.
- Desai AV, Bagchi A, Armstrong AE, van Tilburg CM, Basu EM, Robinson GW, Wang H, Casanova M, Andre N, Campbell-Hewson Q, Wu Y, Cardenas A, Ci B, Ryklansky C, Devlin CE, Meneses-Lorente G, Wulff J, Hutchinson KE, Gajjar A, Fox E. Efficacy and safety of entrectinib in children with extracranial solid or central nervous system (CNS) tumours harbouring NTRK or ROS1 fusions. Eur J Cancer. 2025 May 2;220:115308. doi: 10.1016/j.ejca.2025.115308. Epub 2025 Feb 22.
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stimato)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
- Pediatrico
- Ricaduta
- Refrattario
- Sarcoma di Ewing
- Medulloblastoma
- Tumore solido
- Cancro metastatico
- Sarcoma
- Neuroblastoma
- Carcinoma papillare della tiroide
- Tumori del SNC
- ROS1
- NTRK
- ALK
- Tumori cerebrali
- NTRK1
- NTRK2
- NTRK3
- TRK
- Tirosina chinasi
- Riarrangiamento genico
- Fibrosarcoma infantile
- Cancro al seno secretorio
- Nefroma mesoblastico congenito
- Glioma pontino
- Tumori gliali
- Cancro delle ghiandole salivari (MASC)
- Tumore di Wilms (anaplastico)
Termini MeSH pertinenti aggiuntivi
- Malattie urogenitali
- Malattie del sistema endocrino
- Malattie della bocca
- Malattie stomatognatiche
- Malattie del cervello
- Malattie del sistema nervoso centrale
- Malattie del sistema nervoso
- Processi patologici
- Neoplasie urogenitali
- Neoplasie per sede
- Neoplasie
- Malattie urogenitali maschili
- Malattie renali
- Malattie urologiche
- Malattie urogenitali femminili
- Malattie urogenitali femminili e complicanze della gravidanza
- Attributi della malattia
- Malattie genetiche, congenite
- Neoplasie per tipo istologico
- Neoplasie tiroidee
- Neoplasie delle ghiandole endocrine
- Neoplasie della testa e del collo
- Neoplasie, ghiandolari ed epiteliali
- Adenocarcinoma
- Processi neoplastici
- Neoplasie urologiche
- Carcinoma
- Neoplasie, Neuroepiteliali
- Tumori neuroectodermici
- Neoplasie, cellule germinali ed embrionali
- Neoplasie, tessuto nervoso
- Neoplasie del sistema nervoso
- Neoplasie renali
- Malattie delle ghiandole salivari
- Sindromi neoplastiche, ereditarie
- Neoplasie, Connettivo e Tessuto Molle
- Tumori neuroectodermici, primitivi, periferici
- Tumori neuroectodermici, primitivi
- Osteosarcoma
- Neoplasie, tessuto osseo
- Neoplasie, tessuto connettivo
- Neoplasie Complesse e Miste
- Malattie della tiroide
- Adenocarcinoma, papillare
- Neoplasie della bocca
- Malattie e anomalie congenite, ereditarie e neonatali
- Condizioni patologiche, segni e sintomi
- Cancro alla tiroide, papillare
- Ricorrenza
- Metastasi neoplastica
- Glioma
- Neuroblastoma
- Sarcoma, Ewing
- Sarcoma
- Neoplasie cerebrali
- Neoplasie del sistema nervoso centrale
- Medulloblastoma
- Tumore di Wilms
- Nefroma, mesoblastico
- Neoplasie delle ghiandole salivari
- entrectinib
Altri numeri di identificazione dello studio
- RXDX-101-03
- CO40778 (Altro identificatore: Hoffmann-La Roche)
- 2023-505088-35-00 (Ctis)
- 2023 (Sovvenzione/contratto NIH degli Stati Uniti)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing.
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .